News | News By Subject | News by Disease News By Date | Search News

Melanoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Investors are Antsy After Roche (RHHBY) Suffers Another Late-Stage Trial Flop     9/11/2017
Incyte (INCY) Discloses Promising New Data in Combo Drug Trial With Merck & Co. (MRK)'s Keytruda     9/1/2017
Bristol-Myers Squibb (BMY)'s Opdivo Prevails in Phase III Melanoma Trial     7/6/2017
Array BioPharma (ARRY) Has a Potential Blockbuster Melanoma Drug On Its Hands     2/13/2017
Two Deaths Linked to Bristol-Myers Squibb (BMY)'s Yervoy-Opdivo Combo     11/3/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine     7/7/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues     6/17/2016
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma     5/11/2016
Investors Unhappy as Caladrius Biosciences (CLBS) Kills Phase III Oncology Program, Lays Off 40 in SoCal     1/8/2016
Array BioPharma (ARRY) Surges as Binimetinib Meets Goals in Late-Stage Study     12/16/2015
FDA Grants Full U.S. Approval for Novartis AG (NVS)' Targeted Skin Cancer Combo     11/23/2015
FDA Approves Daiichi Sankyo, Plexxikon's Cobimetinib In Combination With Zelboraf for Advanced Melanoma Patients     11/11/2015
FDA Green Lights Genentech (RHHBY)'s Vemurafenib/Cobimetinib Combo for Melanoma     11/10/2015
Investors Elated as Amgen (AMGN) Wins FDA Approval for First-of-Its-Kind Cancer Killing Virus Drug     10/30/2015
Investors Hold Their Breath as Amgen (AMGN) Inches Toward U.S. Approval for Its New Cancer Immunotherapy T-Vec     10/26/2015

News from Around the Web
Hemopurifier Filters Ebola, Hep C, Metastatic Melanoma: Interview With James A. Joyce, CEO Of Aethlon Medical (AEMD)     7/21/2017
New Microscopic Technique Could Help Detect, Diagnose Metastatic Melanomas, Royal Society Of Chemistry Reveals     5/5/2017
New Technique Spots Pheomelanin In Pale Patients At Risk Of Dangerous Melanoma, Massachusetts General Hospital Reveals     3/8/2017
Genetic Causes Of Higher Melanoma Risk In Men Discovered, Universitat Jaume I de Castellón Reveals     7/22/2016
Microneedle Patch Delivers Localized Cancer Immunotherapy To Melanoma, North Carolina State University Study     3/25/2016
Pharma's Big New Cancer Drug May Be An Old Red Dye     2/26/2016
Vitamin B3 Derivative Cuts Risk Of New Skin Cancers, University of Sydney Study     10/22/2015
Could Laser Skin Test Replace Biopsy For Melanoma? Lancaster University Study     8/24/2015
Coffee Lowers Deadly Skin Cancer Risk, Yale School Of Public Health Study     1/22/2015
Sunscreens Do Not Fully Protect Against Skin Cancer, University Miguel Hernández Study     7/16/2014
Viagra Poses Cancer Risk For Men, JAMA Reveals     6/6/2014
Pine Bark Substance Could Treat Melanoma, Penn State Hershey Melanoma Center Study     5/22/2014
Link Between Viagra And Melanoma Discovered, JAMA Reveals     4/11/2014
Melanoma In Families Linked To Mutations In One Gene, University of Leeds Study     4/3/2014
Sleep Apnea Severity Predicts Aggressiveness of Melanoma, Hospital de Valme Study     9/9/2013

Press Releases
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Omaveloxolone For The Treatment Of Malignant Melanoma     9/14/2017
Array BioPharma (ARRY) Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma     9/12/2017
Idera Pharma (IDRA) Presents Positive Phase I Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy     9/11/2017
Novartis AG (NVS) Phase III Study Demonstrates Adjuvant Tafinlar + Mekinist Reduced The Risk Of Disease Recurrence By 53% In Patients With Resected BRAF V600 Mutation-Positive Melanoma     9/11/2017
Novartis AG (NVS) Phase III Study Demonstrates Adjuvant Tafinlar + Mekinist Reduced The Risk Of Disease Recurrence By 53% In Patients With Resected BRAF V600 Mutation-Positive Melanoma     9/11/2017
Progression-Free Survival Data From Echo-202 Trial Of Incyte (INCY)’s Epacadostat In Combination With Keytruda (Pembrolizumab) Underscore Durability Of Response In Patients With Advanced Melanoma     9/11/2017
NYU Langone Health Release: Alternative Immunotherapy Drug More Effective Than Current Standard Of Care In Treating Advanced Melanoma After Surgical Removal Of Disease     9/11/2017
NewLink Genetics (NLNK) Redeemed Itself After Melanoma Data Wows In Mid-Stage Study     9/8/2017
Progenics (PGNX) Presents Data From AZEDRA Pivotal Phase IIb Study At The 5th International Symposium On Pheochromocytoma And Paraganglioma     9/1/2017
Iovance Biotherapeutics Announces FDA Fast Track Designation For LN-144 For Treatment Of Advanced Melanoma     9/1/2017
Bristol-Myers Squibb (BMY) Data At ESMO 2017 Demonstrate Company’s Innovative Research Approach To Treating Cancer From All Angles     8/31/2017
Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated In Newly Expanded Multicenter Cohort Of 782 Patients     8/29/2017
Pierre Fabre Release: EMA To Start The Review Of The Marketing Authorization Applications For Encorafenib And Binimetinib For The Treatment Of BRAF-Mutant Advanced Melanoma     8/28/2017
Sensus Healthcare (SRTSU) Receives Regulatory Approval To Sell The SRT-100 In China For The Treatment And Prevention Of Keloids     7/26/2017
Bristol-Myers Squibb (BMY) Release: FDA Expands Approval Of Yervoy (Ipilimumab) To Include Pediatric Patients 12 Years And Older With Unresectable Or Metastatic Melanoma     7/24/2017

//-->